Seeking Novel GPCR Targets for Therapeutic Development in Oncology

Cumulus Oncology is developing anti-cancer therapies for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients. In particular, they are interested in identifying and engaging with academics across both small-molecule and biologics platforms that are G-protein-coupled receptor (GPCR) targeted, specifically demonstrating therapeutic activity in the field of oncology. The Cumulus Oncology team will consider single GPCR targets, platform technologies, research projects and engagement with academic experts.

Approaches of Interest:

- Identifying novel GPCR targets that have relevance in an oncology setting, either with expression on the tumour or on other essential mediator cells in the tumour microenvironment
- Research opportunities with hit identification or beyond, or initial biologics development targeting the receptor
- Projects with a clear line of sight to the clinic will be prioritised
- All cancers are within scope, with solid tumours being of highest interest

Out of Scope:

- Drug repurposing approaches, gene therapy and cell-based therapeutics are excluded from this campaign

Developmental Stages of Interest:

- Opportunities at basic research phase to late preclinical research phase are within scope, with a preference for opportunities with target validation
- Opportunities with in vivo validation are of highest interest, although opportunities with in vitro or ex vivo validation will still be considered

Submission Information:

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration:

Cumulus Oncology aims to accelerate oncology innovation into world changing impact. With a flexible business model, Cumulus identifies and sponsors early-stage projects, creating spin-out companies around novel anti-cancer therapies, fast-tracking them through development. They are open to a range of collaboration scenarios, with the most appropriate path determined by the needs of the opportunity. Example outcomes include project funding, licensing assets and research collaborations in which there will be support provided by the seasoned experts from the Cumulus Oncology team.